2zu5: Difference between revisions
No edit summary |
No edit summary |
||
Line 1: | Line 1: | ||
==complex structure of SARS-CoV 3CL protease with TG-0205486== | ==complex structure of SARS-CoV 3CL protease with TG-0205486== | ||
<StructureSection load='2zu5' size='340' side='right' caption='[[2zu5]], [[Resolution|resolution]] 1.65Å' scene=''> | <StructureSection load='2zu5' size='340' side='right'caption='[[2zu5]], [[Resolution|resolution]] 1.65Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>[[2zu5]] is a 1 chain structure | <table><tr><td colspan='2'>[[2zu5]] is a 1 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2ZU5 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=2ZU5 FirstGlance]. <br> | ||
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=ZU5:N-[(BENZYLOXY)CARBONYL]-O-TERT-BUTYL-L-THREONYL-N-[(1R)-4-CYCLOPROPYL-4-OXO-1-{[(3S)-2-OXOPYRROLIDIN-3-YL]METHYL}BUTYL]-L-LEUCINAMIDE'>ZU5</scene></td></tr> | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=ZU5:N-[(BENZYLOXY)CARBONYL]-O-TERT-BUTYL-L-THREONYL-N-[(1R)-4-CYCLOPROPYL-4-OXO-1-{[(3S)-2-OXOPYRROLIDIN-3-YL]METHYL}BUTYL]-L-LEUCINAMIDE'>ZU5</scene></td></tr> | ||
<tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[2ztx|2ztx]], [[2zty|2zty]], [[2ztz|2ztz]], [[2zu1|2zu1]], [[2zu2|2zu2]], [[2zu3|2zu3]], [[2zu4|2zu4]]</td></tr> | <tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[2ztx|2ztx]], [[2zty|2zty]], [[2ztz|2ztz]], [[2zu1|2zu1]], [[2zu2|2zu2]], [[2zu3|2zu3]], [[2zu4|2zu4]]</td></tr> | ||
Line 37: | Line 37: | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
[[Category: | [[Category: Large Structures]] | ||
[[Category: Hsu, M F]] | [[Category: Hsu, M F]] | ||
[[Category: Lee, C C]] | [[Category: Lee, C C]] |
Revision as of 07:32, 13 February 2020
complex structure of SARS-CoV 3CL protease with TG-0205486complex structure of SARS-CoV 3CL protease with TG-0205486
Structural highlights
Function[R1A_CVHSA] The papain-like proteinase (PL-PRO) is responsible for the cleavages located at the N-terminus of replicase polyprotein. In addition, PL-PRO possesses a deubiquitinating/deISGylating activity and processes both 'Lys-48'- and 'Lys-63'-linked polyubiquitin chains from cellular substrates. Antagonizes innate immune induction of type I interferon by blocking the phosphorylation, dimerization and subsequent nuclear translocation of host IRF-3.[1] [2] [3] The main proteinase 3CL-PRO is responsible for the majority of cleavages as it cleaves the C-terminus of replicase polyprotein at 11 sites. Recognizes substrates containing the core sequence [ILMVF]-Q-|-[SGACN]. Inhibited by the substrate-analog Cbz-Val-Asn-Ser-Thr-Leu-Gln-CMK (By similarity). Also contains an ADP-ribose-1-phosphate (ADRP)-binding function.[4] [5] [6] Nsp7-nsp8 hexadecamer may possibly confer processivity to the polymerase, maybe by binding to dsRNA or by producing primers utilized by the latter.[7] [8] [9] Nsp9 is a ssRNA-binding protein.[10] [11] [12] Evolutionary Conservation![]() Check, as determined by ConSurfDB. You may read the explanation of the method and the full data available from ConSurf. Publication Abstract from PubMedHuman coxsackievirus (CV) belongs to the picornavirus family, which consists of over 200 medically relevant viruses. In picornavirus, a chymotrypsin-like protease (3C(pro)) is required for viral replication by processing the polyproteins, and thus it is regarded as an antiviral drug target. A 3C-like protease (3CL(pro)) also exists in human coronaviruses (CoV) such as 229E and the one causing severe acute respiratory syndrome (SARS). To combat SARS, we previously had developed peptidomimetic and zinc-coordinating inhibitors of 3CL(pro). As shown in the present study, some of these compounds were also found to be active against 3C(pro) of CV strain B3 (CVB3). Several crystal structures of 3C(pro) from CVB3 and 3CL(pro) from CoV-229E and SARS-CoV in complex with the inhibitors were solved. The zinc-coordinating inhibitor is tetrahedrally coordinated to the His(40)-Cys(147) catalytic dyad of CVB3 3C(pro). The presence of specific binding pockets for the residues of peptidomimetic inhibitors explains the binding specificity. Our results provide a structural basis for inhibitor optimization and development of potential drugs for antiviral therapies. Structural basis of inhibition specificities of 3C and 3C-like proteases by zinc-coordinating and peptidomimetic compounds.,Lee CC, Kuo CJ, Ko TP, Hsu MF, Tsui YC, Chang SC, Yang S, Chen SJ, Chen HC, Hsu MC, Shih SR, Liang PH, Wang AH J Biol Chem. 2009 Mar 20;284(12):7646-55. Epub 2009 Jan 14. PMID:19144641[13] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See AlsoReferences
|
|